Actinium Pharmaceuticals, Inc.
ATNM· NYSE
ATNMActinium Pharmaceuticals, Inc.
Filed Nov 9, 2018 · 10-Q · 40 days after period end · 0001213900-18-015315
| Metric | Q3 2018 | Q3 2017 | Q3 2016 | Q3 2015 |
|---|---|---|---|---|
| Net Income | -$6.15M | -$6.32M | -$6.60M | -$3.95M |
| EPS Diluted | -$0.06 | -$0.09 | -$0.14 | -$0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Sep 30, 2018 · filed Nov 9, 2018 · 40 d after period end
